Compounds, kits and methods for conferring cytoprotection

A method for combined treatment of a neoplastic disease of a patient by cell therapy and chemotherapy, wherein the neoplastic cells of the patient are PPARg negative cells, comprising the steps of

• isolating cells wherein expression of ABCG2 is inducible by PPARg or PPARg:RXR heterodimer and preferably the cells are PPARg positive cells, from a subject, wherein it is optionally tested whether expression of ABCG2 is inducible in said cells by PPARg or by PPARg:RXR heterodimer,
• activating or increasing the expression of PPARg and, if desired, RXR in said cells, thereby inducing or enhancing the expression of ABCG2 in said cells,
• optionally selecting the cells by a cytotoxic drug transportable by ABCG2,
• differentiating the cells to immature or mature cells and
• introducing the differentiated cells into a patient
• treating the said patient by a chemotherapeutic drug transportable by ABCG2,
• wherein preferably the subject the cells are isolated from is identical with the treated patient.

A method for cell therapy wherein therapeutic cells are selected before administration, comprising the steps of

• isolating cells wherein expression of ABCG2 is inducible by PPARg or PPARg:RXR heterodimer and preferably the cells are PPARg positive cells, from a subject, wherein it is optionally tested whether expression of ABCG2 is inducible in said cells by PPARg or PPARg:RXR heterodimer,
• activating or increasing the expression of PPARg and, if desired, RXR in said cells, thereby effecting a desired alteration in the phenotype of the cells and inducing or enhancing the expression of ABCG2 in the same cells,
• selecting the cells of altered phenotype, said cells expressing ABCG2, by a cytotoxic drug transportable by ABCG2,
• differentiating the cells to immature or mature cells and
• introducing the differentiated cells into a patient,
• wherein preferably the subject the cells are isolated from is identical with the treated patient.